17258-26-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-4,6-dimethylpyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Chloro-4,6-dimethylpyridine is employed as an intermediate for the production of pesticides and other agrochemicals, contributing to the development of effective solutions for crop protection and pest management.
Used in Dye and Pigment Industry:
3-Chloro-4,6-dimethylpyridine is utilized in the manufacturing process of dyes and pigments, providing a range of color options and enhancing the performance characteristics of these products.
Used in Organic Synthesis:
As a building block in organic synthesis, 3-Chloro-4,6-dimethylpyridine is employed in the creation of various organic compounds, expanding the scope of chemical research and development.
Environmental Considerations:

Upstream product

• 7007-92-3 4,6-dimethyl-2,3-dihydropyridazin-3-one 
• 1121-79-5 3-chloro-6-methylpyridazine 
• 64-19-7 acetic acid 
• 81416-97-9 2-Hydroxy-4-oxo-2-methyl-pentansaeure 
• 6641-83-4 2-methyl-4-oxopentanoic acid 
• 23227-96-5 4,5-dihydro-4,6-dimethylpyridazin-3(2H)-one 
• 75-91-2 tert.-butylhydroperoxide 
• 100-52-7 benzaldehyde 

Downstream Products

• 118269-99-1 (4,6-Dimethyl-pyridazin-3-yl)-(2-morpholin-4-yl-ethyl)-amine; hydrochloride 

Relevant academic research and scientific papers

Optimization of a series of multi-isoform PI3 kinase inhibitors

Optimization of the cellular and pharmacological activity of a novel series of PI3 kinase inhibitors targeting multiple isoforms is described.

Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.

A new two-step procedure for functionalized-3(2H)-pyridazinones through homolytic substitution of 3-chloropyridazines

The homolytic substitution of protonated 3-chloro-6-methylpyridazine 1a, followed by hydrolysis with AcOH affords 4- or 4,5-functionalized pyridazinones 3a-c. Less reactivity is found for 3-chloro-6-phenylpyridazine 1b. Hypotheses about these different behaviour patterns are proposed and discussed.

3-Aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities

Minaprine [3[(β-morpholinoethyl)amino]4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effe